Introduction
============

Non-Hodgkin\'s lymphoma (NHL) most frequently arises from the lymphatic system, with the gastrointestinal (GI) tract representing the most commonly involved extranodal site, accounting for half of such cases. In Western series, GI lymphoma occurs principally in the stomach, followed by the small bowel and the colon \[[@B1]\]. Primary involvement of the pancreas in lymphoma is rare, representing a small fraction (less than 1 to 2%) of all pancreatic malignancies \[[@B2]\]. To distinguish primary pancreatic lymphoma (PPL) from secondary involvement of the pancreas by NHL, Behrns\' diagnostic criteria include: a predominant pancreatic mass with gross involvement of only the peripancreatic lymph nodes; no hepatic or splenic involvement; no palpable superficial lymphadenopathy; no enlargement of the mediastinal lymph nodes on chest radiograph; and a normal leukocyte count \[[@B3]\].

Current standard management for PPL has relied mainly on the use of various chemotherapeutic protocols, such as the commonly used regimen of cyclophosphamide, doxorubicin, vincristine and dexamethazone (CHOP). The role of surgery in the management of pancreatic lymphoma has been limited to obtaining diagnostic tissue samples or to bypassing biliary obstruction \[[@B4]\]. More recently, less invasive techniques, such as image-guided percutaneous biopsy, have successfully provided a tissue diagnosis in more than 80% of patients \[[@B5]\].

Although initial results with chemotherapy were encouraging, recent studies with longer follow up of patients with NHL treated with standard chemotherapy with or without radiotherapy have demonstrated higher recurrence rates, particularly for patients with abdominal lymphomas \[[@B6]\]. Given the modest results of standard chemotherapy, the known benefits of surgical resection in the prognosis of other GI lymphomas \[[@B7]\], and recent improvements in clinical outcome after radical pancreatic surgery, the role of surgical resection in the treatment of pancreatic NHL is being reassessed \[[@B2]\].

Here we present the case of a patient initially managed as suffering from adenocarcinoma of the pancreas, who ultimately proved to have PPL. The combined treatment of radical surgical resection and chemotherapy resulted in a good clinical outcome.

Case presentation
=================

A 65-year-old man with a 4-week history of mild epigastric pain radiating to the back (exacerbated after meals), progressive obstructive jaundice, anorexia and weight loss of 3 kg was admitted to our Department of Surgery in November 2005. There was no history of a change in bowel habit, melena, haematochezia, pancreatitis, liver or gallbladder disease. The patient had undergone open repair of an abdominal aortic aneurysm 5 years previously and he was a heavy smoker (40 pack-years) and had a high alcohol intake (300 ml/day).

Upon admission, the patient was icteric, afebrile and had normal vital signs. Physical examination revealed normal bowel sounds, deep jaundice and mild tenderness in the epigastrium and right upper quadrant, without evidence of peripheral lymphadenopathy, palpable mass or hepatosplenomegaly. The patient had an unremarkable haematological profile, but the liver function tests were abnormal: aspartate transaminase (AST) 253 IU/l, alanine transaminase (ALT) 393 IU/l, total bilirubin 7.9 mg/ml, direct bilirubin 6.41 mg/ml, alkaline phosphatase 236 U/l and gamma glutamyl transpeptidase (GGT) 462 U/l. Both serum carcinoembryonic antigen titre and serum carbohydrate antigen titre were normal.

The patient underwent ultrasonography of the liver, biliary tract and pancreas, which revealed a hypoechoic mass at the head of the pancreas. Further assessment of this finding with helical, contrast-enhanced abdominal computed tomography (CT) demonstrated the presence of a large, hypodense, non-homogeneous lesion at the head of the pancreas, with a maximal diameter of 5 cm, without dilatation of the main pancreatic duct (Figure [1](#F1){ref-type="fig"}). Limited lymphadenopathy was also detected in the peripancreatic and the para-aortic regions. The tumour was in contact with the superior mesenteric vein (SMV) without signs of infiltration or encasement of the vein or of the superior mesenteric artery (SMA). The patient also underwent upper GI endoscopy, which revealed mild gastritis in the gastric antrum without evidence of malignancy in the stomach or duodenum. A CT-guided fine needle aspiration (FNA) biopsy was not diagnostic, and the patient was scheduled for exploratory laparotomy.

![Contrast-enhanced helical CT scan. This scan demonstrates the heterogeneous enhancement of a large tumour of the head of the pancreas, in contact with the superior mesenteric vein (SMV), without signs of infiltration or encasement of the vein, or the superior mesenteric artery (SMA).](1752-1947-2-167-1){#F1}

At surgery, a large mass at the pancreatic head was found, which could be easily separated from the contiguous vascular structures with blunt dissection. Interestingly, the tumour did not seem macroscopically to invade the surrounding viscera. A pancreaticoduodenectomy (Whipple procedure) was performed. Histologic evaluation of the surgical specimen revealed extensive involvement of the pancreas by a diffuse, extranodal, high grade, large cell, NHL (centroblastic lymphoma). A neoplastic population, consisting of large non-cleaved lymphoid cells with nucleoli, was seen to surround pancreatic ducts; no lymphoepithelial lesions were present (Figure [2](#F2){ref-type="fig"}). A few small reactive T lymphocytes CD3+ and CD45R0+ (Dako, Glosrtup, Denmark) were observed. Immunohistochemical assessment of the neoplastic cells revealed B lymphoid phenotypes CD20+ (Dako) (Figure [3](#F3){ref-type="fig"}) and CD10+ (Cell Marque Corporation, USA), and the cells were negative for CD3, CD45R0, CD30, CD15, ALK (anaplastic lymphoma kinase), EMA (epithelial membrane antigen) (Dako) and EBN-A2 (Epstein-Barr virus nuclear antigen 2) (Dako). Mitotic activity was very high (Ki67 (Dako) \> 80%) (Fig. [4](#F4){ref-type="fig"}). The tumour was classified as stage IIE according to the Ann Arbor classification \[[@B8],[@B9]\]. The resection margins were free of disease. However, all adjacent lymph nodes in the gastric or peripancreatic region were infiltrated by the tumour.

![Neoplastic lymphoid population surrounding pancreatic duct with no evidence of lymphoepithelial lesions (H/E × 200).](1752-1947-2-167-2){#F2}

![CD20 positivity of neoplastic lymphoid cells (CD20 × 200).](1752-1947-2-167-3){#F3}

![High mitotic activity highlighted by Ki67 expression (Ki67 × 200).](1752-1947-2-167-4){#F4}

In the immediate postoperative course, the patient had several episodes of bilious vomiting shortly after food intake, attributed to oedema of the gastrojejunostomy, which gradually resolved. He also developed a pancreatic fistula which completely resolved after 5 weeks without affecting the patient\'s nutritional status or electrolyte balance.

After surgery the patient underwent four chemotherapeutic sessions consisting of cyclophosphamide, novantrone, vincristine and prednisone, all administered at 3-week intervals. Twenty-one months after surgery the patient was alive and in a good clinical condition.

Discussion
==========

PPL is a very rare neoplasm that may be confused with adenocarcinoma, the most common neoplasm of the pancreas. An extensive review of the international literature has revealed a total of 162 adult patients with biopsy-proven NHL primarily involving the pancreas (Table [1](#T1){ref-type="table"}) \[[@B2],[@B3],[@B10]-[@B17]\]. The clinical manifestation of PPL is non-specific and differentiation from pancreatic adenocarcinoma on a clinical basis is difficult. Only in cases where a patient presents with abdominal pain and a palpable mass without jaundice is the clinical suspicion of pancreatic lymphoma, over adenocarcinoma, enhanced.

###### 

Literature review of primary pancreatic lymphoma: patients\' characteristics, pathologic types, treatment and outcome

  **First author**   **Year**   **Number (*n*)**   **Pathology**                                                                                          **Operation**                                              **Chemotherapy**                                       **Radiotherapy**     **Outcome**                                                      **Response**
  ------------------ ---------- ------------------ ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------ -------------------- ---------------------------------------------------------------- ---------------
  Feather            1951       1                  DLBCL                                                                                                  Total Pancreatectomy                                       None                                                   None                 16 months -- NED                                                 CR
  Acherman           1976       3                  DLBCL                                                                                                  None                                                       CHOP                                                   Yes                  12 months -- NED                                                 CR
  Boddie             1980       2                  DLBCL                                                                                                                                                                                                                                                                                                          
  Freed              1983       1                  NR                                                                                                     Distal Pancreatectomy                                      None                                                   None                 12 months -- NED                                                 CR
  Teefy              1986       2                  DLBCL (1) FLCL (1)                                                                                     None                                                       Yes                                                    Yes                  12 months -- Death                                               PR
  Hart               1987       14                 Histiocytic (9) Poorly diff lymphocytic (2) Well diff lymphocytic (1) T-cell (1) Undifferentiated(1)   Distal Pancreatectomy (1)                                  CHOP (14)                                              1 of 14              NR (1 with resection) Death (7) at 3 to 108 months)              NR
  Webb               1988       9                  DLBCL (6) Follicular mixed (2) Small cleaved (1)                                                       Distal Pancreatectomy (1)                                  MACOP-B (8) CAMEL (1)                                  None                 95 months-NED (1) 21 months-NED (8)                              CR
  Mansour            1989       12                 NR                                                                                                     Distal Pancreatectomy(1)                                   CHOP (11)                                              5 of 9               Death (5) in 2 to 11 months, Recurrence (2) in 3 and 48 months   PR
  Cappell            1989       1                  DLBCL                                                                                                                                                                                                                                                                                                          
  Tuchek             1993       7                  NR                                                                                                     None                                                       CHOP (1) CVP (1) CAMEL (1)                             NR                   Death (4) Alive (3) at 60, 72, 96 months                         CR
  Borrowdale         1994       1                  NR                                                                                                     Whipple                                                    Yes                                                    None                 Death in 12 months                                               CR
  Behrns             1994       12                 DLBCL (7) Small cleaved (2) Mixed (3)                                                                  Whipple (1) Bypass (4)                                     CHOP (4)                                               4 of 12              Death in 38 months at most                                       PR
  Fidias             1995       3                  DLBCL                                                                                                  None                                                       CHOP                                                   None                 Death (1) Recurrence (1) NED in 36 months(1)                     CR (2) PR (1)
  Tanaka             1996       1                  DLBCL (1)                                                                                              Whipple                                                    CHOP                                                   NR                   NED in 36 months                                                 CR
  Ezzat              1996       5                  DLBCL (5)                                                                                              Whipple (1)                                                CHOP (4) CHOP-Ble (1)                                  NR                   NED in 21 to 84 months (4)                                       PR
  Rumstadt           1997       2                  DLBCL (2)                                                                                              Whipple (2)                                                CHOP (1)                                               None                 NED in 29 months                                                 CR
  Bouvet             1997       11                 DLBCL (10) Mixed follicular (1)                                                                        Whipple (1) Distal Pancreaticoduo-denectomy (2)            CHOP-Bleo                                              7of 11               Death (3) Recurrence (2) NED (6)                                 CR
  James              1997       2                  DLBCL (1)                                                                                              None                                                       CHOP (1) PACEBO + CHOP (1)                             1 of 2               NED in 24 months                                                 PR
  Koniaris           2000       8                  DLBCL (7) Nixed follicular (1)                                                                         Whipple (3)                                                CHOP (6) MACOP-B                                       None                 Death (2) NED (3, resection)                                     CR
  Islam              2001       1                  DLBCL                                                                                                  Bypass, biopsy                                             CHOP                                                   None                 NED in 18 months                                                 CR
  Nishimura          2001       19                 DLBCL (15) T-cell (4)                                                                                  Pancreatectomy(10)                                         CHOP (5) Mitomycin Tegafur (1) Unspecified chemo (1)   NR                   1-year actuarial survival B-cell: 51.9% T-cell: 0%               PR
  Boni               2002       1                  DLBCL (1)                                                                                              Laparoscopy-biopsy                                         Chemo (1)                                              None                 NED in 9 months                                                  CR
  Hauksson           2002       1                  DLBCL                                                                                                  PTC stenting biopsy                                        Chemo                                                  NR                   NR                                                               NR
  Volmar             2004       14                 DLBCL (6) follicular (4) Suggestive of lymphoma (3) B lymphoma (1)                                     No                                                         Yes                                                    NR                   Death (3) Alive (11) in a mean 11.8- month followup              2 PR 11 CR
  Nayer              2004^10^   8                  DLBCL (4) High-grade B-cell (1) Low grade B (2) Suspicious (1)                                         None                                                       Chemo (4) Chemo and auto SCT (2) Nr (2)                3 of 8               6 alive at 2 to 6 months                                         PR
  Pezzilli           2004       1                  T-cell lymphoma                                                                                        None                                                       Chemo (1)                                              None                 Death (1)                                                        NR
  Arcari             2005       5                  DLBCL (3) Lymphoplasmacytic (2)                                                                        Pancreatectomy (2)                                         CVP/CHOP(3) CHOP(1) CVP(1)                             2 of 5               Death (3) Alive 2, (1, resection)                                PR
  Grimison           2005       4                  DLBCL (3) Follicular (1)                                                                               None                                                       CHOP(2) Rituximab-CHOP(1) CVP(1)                       4                    Death 132 months Alive 3 at 15, 25, 64 months                    PR
  Ji                 2005       1                  DLBCL (1)                                                                                              Whipple (1)                                                NR                                                     NR                   NR                                                               NR
  Savopoulos         2005       1                  ALCL (1)                                                                                               Biopsy                                                     None                                                   None                 Died 2^nd^postoperative day                                      \-
  Kang               2006       1                  Non-Hodgkin\'s lymphoma                                                                                Biopsy                                                     NR                                                     NR                   NR                                                               NR
  Lin                2006       6                  DLBCL (6)                                                                                              Whipple (2) Pancreatectomy (1) Biliary decompression (1)   Chemo (6)                                              γ-radiotherapy (1)   Death (3) at 2, 37, 49 months NED in 21 months (1)               PR
  Battula            2006       1                  DLBCL (1)                                                                                              Whipple (1)                                                CHOP (1)                                               NR                   NR                                                               NR
  Liakakos           2007       1                  DLBCL (1)                                                                                              Whipple (1)                                                Cyclophosphamide Novantrone Vincristine Prednisone     No                   Alive (2 years)                                                  PR

DLBCL, diffuse large B-cell lymphoma; FLCL, follicular large cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; PACEBO, prednisolone, hydroxydaunorubicine, cyclophosphamide, etoposide, bleomycin, vincristine; CAMEL, cyclophosphamide, adriamycin, vincristine, prednisone; CVP, cyclophosphamide, vincristine, prednisone; SCT, stem cell transplantation; NED, no evidence of disease; NR, not reported; CR, complete response; PR, partial response

There are some biochemical markers which, in conjunction with suspicious clinical manifestations, may help focus the physician\'s attention on the possibility of a pancreatic lymphoma. More specifically, lactate dehydrogenase (LDH) and β2 microglobulin are considered to be tumour markers in lymphoproliferative disorders and have an important positive prognostic value. Serum carbohydrate antigen 19-9 (CA 19-9) level in patients with PPL is usually not elevated. This is in contrast with pancreatic adenocarcinoma, in which almost 80% of cases have a high CA19-9 level \[[@B11]\].

Pancreatic lymphoma, like most extralymphatic lymphomas, is predominantly of intermediate or high-grade histology, with diffuse large B-cell lymphoma being the predominant type \[[@B12]\]. Less than 20% of reported cases demonstrate low-grade histology. The majority of pancreatic lymphomas reported to date in the literature have been classified as of B-cell type, but several cases of T-cell lymphomas have also been described \[[@B13]\].

CT is the most common imaging technique used in the detection and characterization of PPL. On CT, two different morphologic patterns of pancreatic involvement are seen; one is a localized, well-circumscribed tumour with diffuse enlargement infiltrating most of the pancreatic gland. This pattern may mimic the imaging findings of acute pancreatitis with gland enlargement and irregular infiltration of the peripancreatic fat \[[@B14]\]. The well-circumscribed tumoural form can be easily misinterpreted as a ductal adenocarcinoma, especially in patients with dilatation or encasement of the pancreatic and common bile ducts \[[@B15]\]. In contrast, the combination of a bulky, localized tumour in the pancreatic head without significant dilatation of the main pancreatic duct, as seen in our case, strengthens a diagnosis of pancreatic lymphoma over adenocarcinoma. Furthermore, if enlarged lymph nodes are encountered below the level of the renal veins, in association with a large pancreatic tumour, virtual exclusion of adenocarcinoma is possible \[[@B14]\].

Contrast-enhanced CT also offers certain criteria to define the resectability of pancreatic tumours: the absence of extrapancreatic disease; preservation of the fat plane between the tumour and the confluence of superior mesenteric and portal vein (SMPV); and absence of tumour involving or encasing the SMA, coeliac or hepatic arteries \[[@B15]\]. Therefore, one may rely on the CT findings without the need for additional imaging studies in order to evaluate the resectability of a pancreatic head tumour.

Although certain serum abnormalities and CT changes are suggestive of lymphoma, tissue examination is essential for diagnosis. Patients presenting with advanced disease may be diagnosed by peripheral lymph node FNA, core or open biopsy \[[@B2],[@B16]\]. However, there are cases in which the performance of explorative laparotomy becomes mandatory due to the inability of the aforementioned diagnostic modalities to differentiate between pancreatic adenocarcinoma and some other types of pancreatic malignancy \[[@B4],[@B11]\].

At present, the standard protocols for management of pancreatic lymphomas include a number of chemotherapy regimens \[[@B10]\]. The most commonly used regimen is the first-generation therapy CHOP \[[@B2]\], but a range of second- and third-generation regimens are also used. Expected outcomes for all NHL treatments, based on multi-institutional studies using CHOP or an equivalent chemotherapy, with or without radiotherapy, regardless of location, are a complete response rate of approximately 50%, and a partial response rate of approximately 30%. Overall, a 3-year disease-free survival rate of 46% has been reported after such therapies \[[@B6]\].

The observed moderate long-term survival rates for pancreatic NHL with chemotherapy and radiotherapy alone, and the improvements in morbidity and mortality associated with pancreatic surgery, call for a re-evaluation of therapeutic strategies for NHL of the pancreas \[[@B17]\]. A retrospective analysis and a comparison of 15 surgically treated patients with PPL (treated between 1951 and 2000 in several centres) with non-operatively treated stage I or II pancreatic NHL patients (encountered over a similar period) by Koniaris et al. \[[@B2]\] demonstrated markedly improved complete remission and cure rates in the surgically treated group. Detailed comparison between the surgically treated and non-surgically treated groups reveals that age, histologic subtypes and male to female ratio were similar in the two groups. Tumour size was clearly larger in the non-operated group and in many cases patients treated conservatively had unresectable disease. However, the successfully resected group represented a dramatic complete response rate of 100% and long-term survival rate of 94%. These data suggest that for surgically resectable stage I or II pancreatic NHL, resection should be an option in the multimodal therapeutic regimen \[[@B11]\]. To the potential role of surgery in the treatment of pancreatic NHL should be added its well-established place in the management of lymphoma involving other GI organ systems, such as gastric and small bowel lymphomas \[[@B7]\].

Conclusion
==========

When a patient with a pancreatic mass is encountered, preoperative contrast-enhanced CT or magnetic resonance imaging should be obtained. Only in cases in which the resectability of a pancreatic head mass is regarded as impossible, according to the above criteria, should the performance of a definite tissue diagnosis be contemplated. This is achieved with the aid of percutaneous FNA and flow cytometry analysis. If a mass located in the head of the pancreas is regarded as potentially resectable, we advocate explorative laparotomy of the patient. If the intraoperative findings confirm the feasibility of resection of the tumour, pancreaticoduodenectomy is advocated, provided that the surgery is performed by surgeons well-practised with the nuances required for safe pancreatic resection, especially in the case of PPLs, which also respond well to treatment with chemotherapy and radiotherapy alone.
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